---
schema_version: "secwatch.filing_event.v1"
accession: "0001390478-26-000004"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:36:26.018215+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# SELLAS reports FY2025 net loss $26.9M ($0.25/shr); cash $71.8M; Phase 3 REGAL AML trial approaching final analysis

## Summary
- FY2025 net loss $26.9M ($0.25/shr) vs $30.9M ($0.50/shr) in FY2024; cash $71.8M at Dec 31, 2025.
- Received additional $42.6M from warrant exercises in Q1 2026, strengthening balance sheet.
- Phase 3 REGAL trial of GPS in AML nearing final analysis at 80 events; 72 events as of Dec 26, 2025.
- Phase 2 SLS009 in r/r AML showed 46% ORR; expansion into newly diagnosed AML underway, first patient dosed.
- European collaboration with IMPACT-AML to study SLS009 in ~40 newly diagnosed AML patients; enrollment expected Q2 2026.

## SEC filing metadata
- accession: 0001390478-26-000004
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000139047826000004/0001390478-26-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000139047826000004/sls-20260319.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001390478-26-000004
- JSON: https://secwatch.observer/filing/0001390478-26-000004.json
- Plain text: https://secwatch.observer/filing/0001390478-26-000004.txt

## Key facts
- Earnings Releases
  SELLAS Life Sciences Group, Inc. reported financial results for the full year ended December 31, 2025.
  - Period: the full year ended December 31, 2025
  - Result: reported results
  source text: SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the year ended December 31, 2025 and providing a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1390478/000139047826000004/0001390478-26-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.